Cognition Therapeutics Schedules a Type C Meeting with FDA to Align on Endpoints for Phase 3 Trial of Zervimesine (CT1812) in DLB

RegulatoryZervimesinePositive

AI Analysis

Summary

Cognition Therapeutics has scheduled a Type C meeting with the FDA to align on endpoints for a Phase 3 trial of Zervimesine (CT1812) in dementia with Lewy bodies. The meeting represents a regulatory alignment step prior to Phase 3 initiation.

Clinical Trial Data

Phase

Phase 3

Outcome Details

Type C Meeting with FDA to align on endpoints for Phase 3 trial

Importance:5/10

Sentiment:

0.30

FDA meetingDLBPhase 3regulatory alignment

Related Companies

$CGTX

Read the original article

Published by yahoo_finance on September 29, 2026 11:30 AM

Read Original